Class II — Potential Health Hazard

Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

ASPRIRE Cristalle Mammography System (cleared under K212873) installed with the Recalled by FUJIFILM Healthcare Americas Corporation Due to Devices had an unapproved slabbing software function enabled...

Date: June 11, 2025
Company: FUJIFILM Healthcare Americas Corporation
Status: Ongoing
Source: FDA (Device)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact FUJIFILM Healthcare Americas Corporation directly.

Affected Products

ASPRIRE Cristalle Mammography System (cleared under K212873) installed with the ASPIRE Cristalle Digital Breast Tomosynthesis (DBT) Option (approved under P160031).

Quantity: 293 units

Why Was This Recalled?

Devices had an unapproved slabbing software function enabled for use.

Where Was This Sold?

This product was distributed nationwide across all 50 states.

Affected (51 states)Not affected

About FUJIFILM Healthcare Americas Corporation

FUJIFILM Healthcare Americas Corporation has 19 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Device). Last updated March 26, 2026. View original report